Published in ACS Med Chem Lett on December 23, 2012
Benzoquinones as inhibitors of botulinum neurotoxin serotype A. Bioorg Med Chem (2014) 0.98
Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening. J Comput Aided Mol Des (2014) 0.82
Probing BoNT/A protease exosites: implications for inhibitor design and light chain longevity. Biochemistry (2014) 0.81
The C terminus of the catalytic domain of type A botulinum neurotoxin may facilitate product release from the active site. J Biol Chem (2013) 0.76
Newly Designed Quinolinol Inhibitors Mitigate the Effects of Botulinum Neurotoxin A in Enzymatic, Cell-Based and Ex Vivo Assays. J Med Chem (2016) 0.76
Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins (2006) 22.80
Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation. J Mol Biol (1999) 15.00
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
Exploring protein native states and large-scale conformational changes with a modified generalized born model. Proteins (2004) 9.15
Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model (2006) 7.93
Neurotoxins affecting neuroexocytosis. Physiol Rev (2000) 5.42
Substrate recognition strategy for botulinum neurotoxin serotype A. Nature (2004) 2.81
Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective. Toxicon (2001) 2.05
Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org Lett (2006) 1.81
The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison. Angew Chem Int Ed Engl (2008) 1.80
Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J Comb Chem (2006) 1.79
Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol (2007) 1.78
Structure and function of Clostridium botulinum toxins. Microbiol Immunol (1995) 1.60
The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability. Protein Expr Purif (2004) 1.45
Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations. Chem Commun (Camb) (2008) 1.37
Botulinum toxin: clinical use. Parkinsonism Relat Disord (2006) 1.23
Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A. Antimicrob Agents Chemother (2009) 1.21
Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. J Am Chem Soc (2010) 1.14
Botulinum toxin: pharmacology and clinical developments: a literature review. Med Chem (2007) 1.04
Enzymatic autocatalysis of botulinum A neurotoxin light chain. J Protein Chem (2001) 1.04
Protein kinase biochemistry and drug discovery. Bioorg Chem (2011) 1.03
Tandem fluorescent proteins as enhanced FRET-based substrates for botulinum neurotoxin activity. Toxicon (2009) 0.97
Light chain of botulinum A neurotoxin expressed as an inclusion body from a synthetic gene is catalytically and functionally active. J Protein Chem (2000) 0.96
Autocatalytically fragmented light chain of botulinum a neurotoxin is enzymatically active. Biochemistry (2003) 0.92
Tyrosine phosphorylation modulates the activity of clostridial neurotoxins. J Biol Chem (1996) 0.90
Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease. ACS Med Chem Lett (2010) 0.89
Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form. PLoS One (2010) 0.87
Factors affecting autocatalysis of botulinum A neurotoxin light chain. Protein J (2004) 0.86
C. botulinum neurotoxin types A and E: isolated light chain breaks down into two fragments. Comparison of their amino acid sequences with tetanus neurotoxin. Biochimie (1990) 0.78
Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. Science (2002) 2.51
Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol (2007) 2.24
Evidence for ozone formation in human atherosclerotic arteries. Science (2003) 2.22
Revisiting quorum sensing: Discovery of additional chemical and biological functions for 3-oxo-N-acylhomoserine lactones. Proc Natl Acad Sci U S A (2004) 2.05
Bacterial cytotoxins: targeting eukaryotic switches. Nat Rev Microbiol (2005) 1.98
Modulation of gene expression via disruption of NF-kappaB signaling by a bacterial small molecule. Science (2008) 1.93
An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci U S A (2007) 1.85
Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org Lett (2006) 1.81
The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison. Angew Chem Int Ed Engl (2008) 1.80
Deeply inverted electron-hole recombination in a luminescent antibody-stilbene complex. Science (2008) 1.79
Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J Comb Chem (2006) 1.79
Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol (2007) 1.78
Treating cocaine addiction with viruses. Proc Natl Acad Sci U S A (2004) 1.75
Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science (2012) 1.62
Pseudomonas aeruginosa ExoT ADP-ribosylates CT10 regulator of kinase (Crk) proteins. J Biol Chem (2003) 1.60
Uncharacterized 4,5-dihydroxy-2,3-pentanedione (DPD) molecules revealed through NMR spectroscopy: implications for a greater signaling diversity in bacterial species. Angew Chem Int Ed Engl (2012) 1.55
Unique substrate recognition by botulinum neurotoxins serotypes A and E. J Biol Chem (2006) 1.54
Fluorescent cocaine probes: a tool for the selection and engineering of therapeutic antibodies. J Am Chem Soc (2005) 1.48
Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry (2006) 1.48
A vaccine strategy that induces protective immunity against heroin. J Med Chem (2011) 1.47
Optimizing gene suppression in schistosomes using RNA interference. Mol Biochem Parasitol (2007) 1.47
The C-terminus of botulinum neurotoxin type A light chain contributes to solubility, catalysis, and stability. Protein Expr Purif (2004) 1.45
Vaccination against weight gain. Proc Natl Acad Sci U S A (2006) 1.45
N-(3-oxo-acyl)homoserine lactones signal cell activation through a mechanism distinct from the canonical pathogen-associated molecular pattern recognition receptor pathways. J Biol Chem (2006) 1.42
Glycosylated SV2 and gangliosides as dual receptors for botulinum neurotoxin serotype F. Biochemistry (2009) 1.41
Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol Biochem Behav (2009) 1.39
MPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. Pharmacol Biochem Behav (2007) 1.39
Subunit vaccine against the seven serotypes of botulism. Infect Immun (2007) 1.39
Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations. Chem Commun (Camb) (2008) 1.37
Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem (2004) 1.37
Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs). J Immunol Methods (2007) 1.36
Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins. Annu Rev Microbiol (2008) 1.35
Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery. Mol Pharm (2007) 1.35
In vivo rho GTPase-activating protein activity of Pseudomonas aeruginosa cytotoxin ExoS. Infect Immun (2002) 1.35
Histidine kinases as targets for new antimicrobial agents. Bioorg Med Chem (2002) 1.33
Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc (2011) 1.31
Functions of the tegument of schistosomes: clues from the proteome and lipidome. Int J Parasitol (2006) 1.30
Mechanism of substrate recognition by botulinum neurotoxin serotype A. J Biol Chem (2007) 1.30
Synthesis and biological validation of a ubiquitous quorum-sensing molecule. Angew Chem Int Ed Engl (2004) 1.29
The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication. ACS Chem Biol (2006) 1.26
A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol Pharm (2010) 1.26
Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci U S A (2009) 1.26
Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. Chem Commun (Camb) (2006) 1.25
Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci U S A (2013) 1.24
A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One (2012) 1.24
Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis. Proc Natl Acad Sci U S A (2004) 1.21
A credit-card library approach for disrupting protein-protein interactions. Bioorg Med Chem (2005) 1.20
Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol Biochem Behav (2005) 1.19
Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors. Bioorg Med Chem Lett (2007) 1.19
Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol Ther (2011) 1.18
A method for the generation of combinatorial antibody libraries using pIX phage display. Proc Natl Acad Sci U S A (2002) 1.18
Interspecies and interkingdom communication mediated by bacterial quorum sensing. Chem Soc Rev (2008) 1.17
Suppressing glucose transporter gene expression in schistosomes impairs parasite feeding and decreases survival in the mammalian host. PLoS Pathog (2010) 1.17
Intracellular localization modulates targeting of ExoS, a type III cytotoxin, to eukaryotic signalling proteins. Mol Microbiol (2002) 1.17
Auto-ADP-ribosylation of Pseudomonas aeruginosa ExoS. J Biol Chem (2002) 1.16
Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. J Am Chem Soc (2010) 1.14
Calcitonin gene-related peptide inhibits local acute inflammation and protects mice against lethal endotoxemia. Shock (2005) 1.14
An unexpected switch in the modulation of AI-2-based quorum sensing discovered through synthetic 4,5-dihydroxy-2,3-pentanedione analogues. J Am Chem Soc (2008) 1.14
Intracellular membrane localization of pseudomonas ExoS and Yersinia YopE in mammalian cells. J Biol Chem (2003) 1.14
Association of botulinum neurotoxin serotypes a and B with synaptic vesicle protein complexes. Biochemistry (2007) 1.14
Aptamer selection by high-throughput sequencing and informatic analysis. Biotechniques (2011) 1.14
Antibody interference with N-acyl homoserine lactone-mediated bacterial quorum sensing. J Am Chem Soc (2006) 1.13
Caenorhabditis elegans exoskeleton collagen COL-19: an adult-specific marker for collagen modification and assembly, and the analysis of organismal morphology. Dev Dyn (2003) 1.13
Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev Vaccines (2008) 1.13
Structural basis for ligand recognition and discrimination of a quorum-quenching antibody. J Biol Chem (2011) 1.13
Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor. Proc Natl Acad Sci U S A (2011) 1.12
Gangliosides as high affinity receptors for tetanus neurotoxin. J Biol Chem (2009) 1.12
Defining the mode of action of tetramic acid antibacterials derived from Pseudomonas aeruginosa quorum sensing signals. J Am Chem Soc (2009) 1.12
A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats. Biol Psychiatry (2012) 1.11
Substrate recognition of VAMP-2 by botulinum neurotoxin B and tetanus neurotoxin. J Biol Chem (2008) 1.11
Development of immunopharmacotherapy against drugs of abuse. Curr Drug Discov Technol (2004) 1.10
Stepwise engineering of heterodimeric single domain camelid VHH antibodies that passively protect mice from ricin toxin. J Biol Chem (2013) 1.10
Multiple pocket recognition of SNAP25 by botulinum neurotoxin serotype E. J Biol Chem (2007) 1.10
Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun (2005) 1.10
N-H insertion reactions of primary ureas: the synthesis of highly substituted imidazolones and imidazoles from diazocarbonyls. J Org Chem (2004) 1.09
Recombinant holotoxoid vaccine against botulism. Infect Immun (2007) 1.09
A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm (2006) 1.09
Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res (2006) 1.08
Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology (2011) 1.07
Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett (2010) 1.07
Medicinal chemistry as a conduit for the modulation of quorum sensing. J Med Chem (2010) 1.06
Total synthesis of the depsipeptide FR-901375. J Org Chem (2003) 1.06
A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun (2013) 1.06
Ezrin/radixin/moesin proteins are high affinity targets for ADP-ribosylation by Pseudomonas aeruginosa ExoS. J Biol Chem (2004) 1.05
Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res (2011) 1.04
Soluble polymers as scaffolds for recoverable catalysts and reagents. Chem Rev (2002) 1.04
How bacterial ADP-ribosylating toxins recognize substrates. Nat Struct Mol Biol (2004) 1.04
Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate. Biochemistry (2006) 1.04
Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon (2010) 1.04
Heritable transgenesis of Parastrongyloides trichosuri: a nematode parasite of mammals. Int J Parasitol (2006) 1.04